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Abstract: Neurofilament light (NFL) has proved to be a good prognostic factor in multiple sclerosis
(MS), as its level is proportionally elevated with extended neuraxonal damage. The involvement
of the kynurenine pathway in neuroinflammation has been proved. The precursor of this pathway
is the essential amino acid tryptophan, which is catabolized 95% towards kynurenine metabolites.
Quinolinic acid (QUIN) within the brain is only produced in activated microglia and macrophages,
leading to axonal degeneration via the activation of N-Methyl-D-aspartate receptors. Neopterin
is a biomarker for inflammation produced by macrophages. The association of these biomarkers
has not previously been investigated. Our aim was to assess whether there is an association of
the neurodegenerative biomarker NFL with the markers of neuroinflammation, e.g., kynurenine
metabolites and neopterin, in the cerebrospinal fluid (CSF). CSF samples of patients with MS (pwMS;
n = 37) and age-matched controls (n = 22) were compared for NFL levels by ELISA, while the
kynurenine pathway metabolites tryptophan and neopterin were detected with mass spectrometry.
Spearman’s correlation showed that NFL is an independent predictor of neurological disability
in the MS group. Significant correlations were found between NFL, neopterin, and QUIN, and
between kynurenine and neopterin. Receiver operating characteristic (ROC) curve analysis was used
to plot the top three best predictors of MS-related disability that yielded the best specificity and
sensitivity. Normalized NFL (AUC: 0.923), QUIN (AUC: 0.803), and neopterin (AUC: 0.843) were
the best independent predictors of neurological disability in pwMS. The CSF NFL and CSF QUIN,
together with neopterin, were elevated in the CSF of pwMS compared to controls. The combination
of the neurodegenerative biomarkers together with biomarkers of neuroinflammation could provide
additional information on the underlying pathomechanism of disease activity, which is essential for
the identification of patients at risk of developing cumulative disabilities.
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1. Introduction
Neurofilament light chains (NFLs), which belong to the 68 kDa-sized members of the family
of filament proteins [1], form the cytoskeleton of neurons. The protein serves as a good prognostic
biomarker for different neurodegenerative disorders including multiple sclerosis (MS) [2], and shows an
age-dependent increase in both the cerebrospinal fluid (CSF) and the serum with good correlation [3,4].
Thus, tissue injury and regeneration are not restricted to MS; neurofilaments are not specific for the
disease, but they can give a picture of its activity and severity [5].
The kynurenine pathway leads to nicotinamide adenine dinucleotide (NAD+) production by
degradation of the essential amino acid tryptophan, which is a precursor for serotonin and melatonin
as well (Figure 1). Tryptophan is catabolized 95% towards kynurenine metabolites by the rate limiting
enzyme indoleamine-2,3-dioxygenase (IDO). Its metabolite, quinolinic acid (QUIN), is produced by
activated microglia and resident macrophages in the central nervous system (CNS), but not by neurons
and astrocytes. QUIN is involved in neuronal death; it acts as an agonist of N-methyl-D-aspartate
(NMDA) receptors [6,7] and directly increases glutamate transmission by inhibiting astrocyte glutamate
removal and stimulating glutamate release from neurons [8,9]. It acts as a neurotoxic agent by causing
blood–brain barrier breakdown, and leads to oxidative stress by inducing lipid peroxidation and
mitochondrial dysfunction [10,11] in experimental animal models. It can also induce apoptosis of
myelin-producing oligodendrocytes [12]. Neopterin is a nonspecific marker of inflammation present
during viral as well as immunological inflammatory processes. Interferon-gamma is capable of
increasing neopterin production in macrophages [13,14].
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Figure 1. Kynurenine metabolism from its precursor tryptophan to nicotinamide adenine dinucleotide
(NAD+) production. Abbreviations: 3HAO—3-hydroxyanthranilate oxygenase, ACMSD—2-amino-
3-carboxymuconate semialdehyde decarboxylase, IDO—indoleamine-2,3-dioxygenase, KAT—
kynurenine aminotransferase, KMO—kynurenine-3-monooxygenase, NAD+—nicotinamide adenine
dinucleotide, QPRT—quinolinic acid phosphoribosiltransferase, TDO—tryptophan-2,3-dioxygenase.
We analyzed data from patients with MS (pwMS) regarding NFL levels in the CSF at diagnostic
lumbar puncture (LP) and compared them with tryptophan, kynurenine pathway metabolites, and
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neopterin in the CSF, retrospectively. As extensive research supported that NFL proved to be a stable,
reliable biomarker in MS, especially in the CSF for axonal damage, it served as a proven biomarker
for comparison. We hypothesized that elevated quinolinic acid and decreased kynurenic acid levels
in the MS group would reflect the pathological processes. A positive correlation of these biomarkers
involved in neurodegeneration (NFL) and neuroinflammation (QUIN and neopterin) was expected in
pwMS when compared to the control group.
2. Results
2.1. NFL Levels Were Measured with ELISA
We measured the NFL level in 37 CSF samples of pwMS and 22 CSF samples of controls
(demographic data shown in Table 1). Significantly higher NFL levels were found in the CSF of
pwMS compared to controls (Mann–Whitney U test, p < 0.0001, median ± SEM 3280.36 ± pg/mL vs.
572.50 ± 70.23 pg/mL). As linear regression with adjusted R-squared values showed age-dependent
changes with regard to NFL (p = 0.016, R = 0.545, R-square = 0.297, adjusted R-square = 0.256), we
corrected for this effect. The age-corrected NFL values for pwMS were 3021.65 ± 410.13 pg/mL vs.
547.19 ± 66.36 pg/mL (mean ± SD) for controls.
Table 1. Demographics of the patients and controls.
pwMS Controls
No. 37 22
No. male:female 18:19 11:11
median age (year±SEM) 34.1 ± 9.9 38.6 ± 10.6
clinical course
(2017 diagnostic criteria)
CIS n = 5 (n = 2 converted later to RMS)
RMS n = 32
symptomatic n = 12
NIND n = 10
EDSS at onset
(median±SEM) 2.0 ± 1.4
EDSS at FUP
(median±SEM) 1.0 ± 2.3
CIS—clinically isolated syndrome, EDSS—expanded disability status scale, FUP—follow up, RMS—relapsing
multiple sclerosis, SEM—standard error of mean, pwMS—patients with multiple sclerosis.
The normalized NFL values gave better specificity and sensitivity (uncorrected for age area under
the curve (AUC) AUCNFL = 0.890 and corrected for age AUCNFLc = 0.923, respectively, Figure 2).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 4 of 14 
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2.2. Tryptophan, Kynurenine Pathway Metabolites, and Neopterin Were Measured with Mass Spectrometry
The CSF values of tryptophan, kynurenine metabolites, and neopterin of the 37 pwMS and
22 controls are highlighted in Table 2 and Figure 3. The values are expressed as the mean ± SD.
To evaluate the significance of the differences between the metabolite levels of disease and control
groups, we performed two-tailed independent t-tests. For multiple comparisons, the p value was
considered significant if the p value was less than 0.00625 (p < 0.05/8).
Table 2. Cerebrospinal fluid (CSF) values of tryptophan, kynurenine pathway metabolites, and neopterin.
Group pwMS (n = 37) Controls (n = 22) p Value
tryptophan (nmol/L) 1642.57 ± 510.96 1864.17 ± 530.83 p = 0.12
kynurenine (nmol/L) 33.58 ± 11.07 27.99 ± 8.88 p = 0.049
kynurenic acid (nmol/L) 1.87 ± 0.66 1.73 ± 0.48 p = 0.42
QUIN (nmol/L) 26.78 ± 9.38 18.69 ± 6.59 * p = 0.001
piconilic acid (nmol/L) 17.36 ± 7.16 18.31 ± 5.16 p = 0.59
5HIAA (nmol/L) 83.99 ± 39.95 100.97 ± 36.45 p = 0.11
neopterin (nmol/L) 6.29 ± 2.40 3.51 ± 1.61 ** p < 0.0001
The values are given as mean ± SD. * p < 0.00625, ** p < 0.000125. Abbreviations: QUIN—quinolinic acid,
5HIAA—5-hydroxy-indolacetic acid.
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2.3. Correlations between NFL, Tryptophan, Kynurenine Pathway Metabolites, and Neopterin
NFL proved to be an independent parameter in the MS group. The correlations between the
different metabolites and NFL are shown in Table 3 and in scatterplots in Figure 4. Correlations
of 0.01 level significance were found between NFL and QUIN, NFL and neopterin (NEO),
kynurenine (KYN) and NEO, QUIN and NEO, KYN and QUIN, and kynurenic acid (KYNA) and
5-hydroxy-indolacetic acid (5HIAA). Correlations of 0.05 significance level were detected between
KYNA and QUIN, and between tryptophan (TRP) and QUIN. The correlations between KYNA and
5HIAA, KYN and QUIN, KYNA and QUIN, as well as between TRP and QUIN, are most probably
due to the downstream metabolism, which explains these connections. More interestingly, there was
a strong positive correlation between NFL, QUIN and NEO, and between KYN and NEO, which
points to a positive correlation between the biomarkers of neuroinflammation and axonal degeneration.
The only negative correlation was found between TRP and QUIN, which most probably indicates an
increased formation of QUIN from the precursor, TRP.
Table 3. Correlation between NFL, tryptophan, kynurenine pathway metabolites, and neopterin levels.
Spearman’s rho
Correlation Coefficient NFL TRP KYN KYNA QUIN PA 5HIAA NEO
NFL 1 −0.118 0.165 0.095 0.366 ** −0.016 −0.139 0.364 **
TRP −0.118 1 0.082 −0.125 −0.313 * 0.081 0.113 −0.225
KYN 0.165 0.082 1 0.251 0.508 ** −0.203 0.026 0.386 **
KYNA 0.095 −0.125 0.251 1 0.327 * 0.030 0.576 ** 0.067
QUIN 0.366 ** −0.313 * 0.508 ** 0.327* 1 −0.121 −0.017 0.513**
PA −0.016 0.081 −0.203 0.030 −0.121 1 −0.018 −0.074
5HIAA −0.139 0.113 0.026 0.576 ** −0.017 −0.018 1 −0.217
NEO 0.364 ** −0.225 0.386 ** 0.067 0.513 ** −0.074 −0.217 1
* Correlation is significant at the 0.05 level (2 tailed), ** correlation is significant at the 0.01 level (2
tailed). 5HIAA—5-hydroxy-indolacetic acid, KYNA—kynurenic acid, KYN—kynurenine, NEO—neopterin,
NFL—neurofilament light chain, PA—picolinic acid, QUIN—quinolinic acid, TRP—tryptophan.
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NFL, kynurenine metabolites and NEO. *p < . , ** p < .000125. Blue ring-plots: controls,
red lots: pwMS. Abbreviations: 5HIAA—5-hydroxy-indol etic acid, KYNA—kynurenic acid,
KYN—kynurenine; NEO—neopterin, NFL—neurofilament light chain, PA—picolinic acid, QUIN—
quinol ic acid, TRP—trypto han.
A receiver operating characteristic (ROC) curve was used to plot the tr te s. the
false positive rat of the different m asured pa amete s. It depic s the umulative distribution function
of the detection probability on the y-axis and the cumulative distribution function of the false-alarm
probability on the x-axis.
Normalized NFL (AUC: 0.923), QUIN (AUC: 0.803), and neopterin (AUC: 0.843) were the top three
best predictors of MS-related disability according to ROC curve analysis among the eight observed
values (Figures 5 and 6).
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The expanded disability status scale (EDSS) point at the time of LP correlated well with tryptophan,
kynurenic acid, and QUIN levels (ANOVA; p < 0.001): for tryptophan r2 = 0.128; y = 9.42*1016-0.57 * x;
for kynurenic acid r2 = 0.128, y = 9.423*1016-0.57 * x; and for QUIN r2 = 0. 405, y =−1.23*10-15 + 0.09 * x.
3. Discussion
NFL seems to be a robust marker of ongoing disease activity in pwMS. Moreover, NFL
levels correlate well with conversion to clinically definitive MS [15,16], increased number of
relapses, confirmed disability wors ni g, treatment and MRI utcomes [17], spi al cord and brain
atrophy [4,18,19], and different clinical forms such as radiologically isolated syndrome [20], clinically
isolated syndrome (CIS) ([21], relapsing-remitting MS (RRMS) [16,22,23], and primary progressive
MS (PPMS) [24]. NFL levels correlate significantly with the presence of gadolinium enchancing
lesions and T2 lesion load [20]. Independent of treatment, high NFL levels before treatment are the
strongest predicting factor of relaps s, accelerated brain volume loss and MRI a tivity at treatment
effect evaluation 24 months after treatment [22]. Several treatments decrease the NFL levels such
as natalizumab [25], fingolimod [26,27], and int fe on-b ta [22]. G nder differenc s regarding NFL
levels have not yet been reported in the literature.
At lower concentrations, QUIN disturbs neuronal homeostasis at the cellular level by
phosphorylating the neurofilament subunits [28], while high concentrations induce apoptotic cell
death in striatal neurons in cell culture [29,30]. Cocultured astrocytes and neurons interact to
protect themselves against QUIN damage [31]. In addition, these neuronal interactions preserve cell
morphology and cytoskeletal structure [31]. Furthermore, the neuronal cytoskeleton was found to
be more responsive than the cytoskeleton of the astrocytes to QUIN damage, since a ten times
higher concentration was needed for cytoskeleton injury in astrocytes than in neurons [30,31].
The morphological changes induced by QUIN interfere with axonal transport and with other
axonal cytoskeleton functions [29]. High QUIN levels are associated with neuronal damage in
neurodegenerative conditions [28,32]. Furthermore, QUIN treatment led to the disruption of the
cytoskeletal homeostasis of neurons, and excitotoxic dendritic damage could be shown [33]. The initial
locations of these injuries were in the dendrites [34], and this resulted in apoptosis or necrosis of the
neuron, depending on the extent of the damage [35]. In human studies, QUIN levels were increased
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in both the serum and CSF of pwMS [36]. Lim and coworkers found that QUIN can differentiate
MS subtypes [37]. It is proposed that the modulation of the kynurenine pathway could decrease
neuroinflammation due to the inhibition of the IDO enzyme and the kynurenine monooxygenase
(KMO) enzymes. These proposals are based on previous findings that KMO inhibitors decrease MS
disease activity in mouse experimental allergic encephalomyelitis (EAE). In kynurenine-treated mice,
a delay in relapse was observed. Kynurenine pathway activation results in two opposite events;
the short-term benefits arise from decreased T cell proliferation, leading to immunosuppression, while
chronic activation of the kynurenine pathway enzymes enhances production of neurotoxic metabolites
and plays a role in preventing the innate repair mechanism of remyelination. In MS, increased
QUIN was associated with the loss of oligodendrocytes, astrocytes, and neurons, and decreased
neuroprotective metabolites such as kynurenic acid and picolinic acid [38].
Rejdak and coworkers found higher CSF levels of KYNA during relapse and lower levels during
remission in relapsing pwMS [39,40]. Interestingly, we have not found changes in CSF KYNA levels,
similarly to Aeinehband and coworkers [36]. After stratification based upon the different disease
subgroups, relapsing pwMS had a metabolic shift of the kynurenine pathway towards the neurotoxic
path (elevated QUIN), while progressing pwMS displayed a trend toward downregulation of the
kynurenic pathway. Secondary and primary progressive pwMS differed in KYNA levels, which was
much lower in the former group of patients [36].
In MS, besides tissue damage due to relapse, progression independent of relapse activity (PIRA)
leads to ongoing accumulation of disability in progressive as well as in relapsing forms of the disease.
This chronic condition is characterized by ongoing brain tissue damage, also regarded as faster
aging [41–43]. Other pathological changes are mitochondrial dysfunction, oxidative stress, and slowly
enlarging lesions (SELs) detected on the MRI. SELs may reflect chronic inflammation caused by
microglia or macrophage populations resident in the CNS, or they can be present due to secondary
Wallerian degeneration [44]. Activated microglia-derived macrophages produce more QUIN than
activated microglia, while CSF resident cells do not possess all the enzymes of the kynurenine pathway
and are therefore unable to synthesize great amounts of QUIN; however, they can still produce KYN.
Astrocytes in the CNS in turn can release extra KYN, which serves as a source for QUIN by monocytes
and microglia-derived macrophages. The high levels of QUIN produced by monocytes and these
macrophages are toxic to neurons and oligodendrocytes [45]. These features can lead to demyelination
and parallelly occurring axonal damage in MS. Further studies are needed to depict the ongoing disease
activity in order to allow for the identification of patients at risk of developing cumulative disabilities.
Just as in a recent study in which association between serum NFL and QUIN levels was found in
preclinical Alzheimer’s disease [46], we found a strong positive correlation between NFL normalized
for age, neopterine, and QUIN, in the CSF of pwMS. This is the first study in which neurodegeneration
and neuroinflammation showed a tight correlation in the CSF of MS patients involving independent
parameters such as NFL for axonal degeneration, neopterin as a general marker for inflammation,
and QUIN as a potential biomarker for neuroinflammation. The limits of the present study are the
low subject numbers and that the data are limited to the CSF, which requires an invasive method to
obtain biomarkers.
4. Methods
4.1. Standard Protocol Approvals, Registrations, and Patient Consents
This study was approved by the local ethical committee (No. 143/25.06.2015). All patients
participated voluntarily and gave their informed consent at the admission to the hospital for carrying
out medical examinations, for collecting sera and CSF samples for our biobank at lumbar puncture (LP),
or later during follow-up. The samples were processed and analyzed according to the international
standardized biobanking consensus protocol of the BIOMS-Eu network [47].
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4.2. Patients and Controls
Inclusion criteria for MS patients were age > 18 years, LP at diagnosis, at least a 12-month
follow-up, and available samples in the biobank obtained between 2012 and 2018. The patients were
prospectively followed up, meeting an MS specialist at least four times a year. The diagnosis was
based on the revised McDonald criteria [48], which accepted the oligoclonal bands as a proof for
dissemination in time, allowing an early diagnosis and treatment. At the consultations, EDSS scores,
disease activity, clinical forms, and treatment were assessed regularly. All patients underwent LP
during the diagnostic procedure with parallel CSF and blood sampling. None of the patients received
MS treatment at the time of LP.
To rule out age-related differences, the CSF samples of pwMS (n = 37) were compared with age
and gender-matched controls (n = 22) with symptomatic neurological disorders (n = 12; 8 headache,
2 anxiety, 1 seizure, 1 low back pain) and patients with non-inflammatory neurological diseases (NIND,
n = 10; 4 lacunar stroke, 4 benign intracranial hypertension, 1 transient global amnesia, and 1 mild
ocular myasthenia gravis), and followed for at least 2 years to exclude other underlying pathologies.
Patients with known diseases of predictably high NFL levels were excluded (e.g., severe stroke,
NMDA-receptor encephalitis).
4.3. NFL Analysis
CSF NFL levels were measured with a commercially available sensitive sandwich ELISA kit
(NFL-light ELISA kit; UmanDiagnostics, Umeå, Sweden) using a Multiskan ® EX ELISA scanner
(Thermo Electron Corporation, Finland, precision CV < 0.5% (0.3–1.5 Abs) at 405 nm; CV < 1%
(1.5–2 Abs) at 405 nm; accuracy ± 2.0% or ± 0.007 Abs whichever is greater, typical value ± 1%
(0–2.0 Abs) at 405 nm. The detection limit of this method is given as the limit of quantification of the
assay, which was 310 pg/mL. The inter and intraassay variations were below 10%.
4.4. Tryptophan, Neopterin, and Kynurenine Pathway Metabolite Analysis
Parallel to the NFL analysis, CSF samples were measured for kynurenine pathway metabolites.
All reagents and metabolites were analytical reagent grade and were purchased from Sigma-Aldrich
or Merck. Deuterated internal standards were purchased from Cambridge Isotope Laboratories and
Medical Isotopes Inc. Concurrent analysis of tryptophan, kynurenine, quinolinic acid, kynurenic acid,
picolinic acid, 5-hydroxyindoleacetic acid, and neopterin was performed with LC-MS/MS as described
by Fuertig et al. [49], using an injection volume of 15 µL of the prepared extract from each samples.
The LC-MS/MS system consisted of a PerkinElmer Flexar UHPLC system (two FX-10 binary pumps,
solvent manager, autosampler, and thermostatic oven; all PerkinElmer Inc.) coupled with an AB
SCIEX QTRAP 5500 MS/MS triple quadrupole mass spectrometer and controlled by the Analyst 1.6.2
software (both AB Sciex, Framingham, MA USA). MS-analyses were performed in positive electrospray
ionization mode (ESI); interface parameters were set as follows: curtain gas 40 psi; ionspray voltage
5500, probe temperature 700 ◦C; nebulizer gas 40 psi; heather gas 40 psi. The quadrupoles operated in
multiple reaction monitoring mode. Dwell time was set to 20 msec of each transition, using nitrogen as
collision gas.
4.5. Statistical Analysis
Statistical calculations were performed with the IBM SPSS Statistics 24 software (IBM Corp.,
Armonk, NY, USA).
Except in the case of NFL, all measured parameters had normal distribution in both patients and
controls. Therefore, Mann–Whitney U test was performed for NFL, and the data were presented in
median ± SEM. For the other parameters independent sample t-test was used, and the values were
given in mean ± SD. NFL proved to be age dependent by linear regression (p = 0.016; r2 linear = 0.297,
y = 1.28*102 + 15.77 * x) and served as a basis for normalization for further use.
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We performed Spearman rank correlation to analyze the relations between the measured metabolites.
A receiver operating characteristic (ROC) curve was used to plot the true positive rate vs. the
false positive rate of the different measured parameters.
5. Conclusions
The recent diagnostic criteria of MS [45] enable the early stage diagnosis of this potentially disabling
disease beginning mainly in young adulthood, thus also facilitating early treatment. In MS, disability
accumulates not only when relapse occurs but also between relapses, pointing to a continuously
ongoing neurodegeneration besides neuroinflammation. Early, appropriately effective treatment
can hinder the accumulation of disability. We found that CSF NFL and CSF QUIN, together with
neopterin, were elevated in the CSF of pwMS compared to controls. Combined measurement of
the neurodegenerative biomarkers together with biomarkers of neuroinflammation could provide
additional information on the underlying pathomechanism of disease activity, which is essential to
identify patients at risk of developing cumulative disabilities.
Reliable biomarkers are needed which could additionally direct attention towards patients who
need highly effective disease-modifying treatment at the early stages of the disease.
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